Benjamin Cohen, MD
Cardiovascular Disease · West Hills, CANPI 1114991767
Payments from drug & device makers
Across 401 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Medtronic$1K
- Heartflow, Inc.$714
- Boston Scientific$600
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$546
- E.r. Squibb & Sons, L.L.C.$493
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,81899%
- Education$110%
- Other$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 75 | $1,168 |
| Medtronic(2 entities) | 25 | $1,081 |
| Heartflow, Inc. | 26 | $714 |
| Boston Scientific | 19 | $600 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $546 |
| E.r. Squibb & Sons, L.L.C. | 41 | $493 |
| Amgen | 22 | $457 |
| Abbott | 17 | $429 |
| Pfizer | 28 | $389 |
| Johnson & Johnson | 18 | $381 |
| Merck | 16 | $347 |
| Sanofi-aventis U.S. LLC | 13 | $340 |
| Boehringer Ingelheim | 13 | $301 |
| Amarin Pharma, Inc. | 14 | $282 |
| GE HealthCare | 2 | $169 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $148 |
| Alnylam Pharmaceuticals Inc. | 4 | $99 |
| AstraZeneca | 6 | $92 |
| Kestra Medical Technology Services, Inc. | 3 | $87 |
| Novo Nordisk | 4 | $86 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Cvrx, Inc. | 2 | $70 |
| Abiomed | 2 | $66 |
| Resmed Corp | 1 | $61 |
| Kowa Pharmaceuticals America, Inc. | 2 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $54 |
| Baxter Healthcare | 1 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $42 |
| Cleerly, Inc. | 1 | $37 |
| Bayer | 2 | $34 |
| Braemar Manufacturing, LLC | 1 | $30 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Itamar Medical Inc | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$391
- FFRct$277
- Micra$150
- COREVALVE EVOLUT R$142
- GENERAL PAIN MANAGEMENT$127
- LifeVest$123
- Watchman$102
How this compares
$8,876 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $243,717 |
| XareltoRivaroxaban | 63 | $95,609 |
| EntrestoSacubitril/Valsartan | 75 | $94,867 |
| Repatha SureclickEvolocumab | 50 | $59,837 |
| JardianceEmpagliflozin | 53 | $58,188 |
| FarxigaDapagliflozin Propanediol | 39 | $45,805 |
| VascepaIcosapent Ethyl | 43 | $26,923 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $14,339 |
| Praluent PenAlirocumab | 16 | $12,508 |
| NexletolBempedoic Acid | 21 | $11,888 |
| MultaqDronedarone Hcl | 13 | $11,579 |
| MounjaroTirzepatide | 11 | $11,573 |
| OzempicSemaglutide | 11 | $9,139 |
| Rosuvastatin Calcium | 342 | $8,761 |
| Ezetimibe | 214 | $7,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $389 | $243,717218 claims |
| Johnson & JohnsonXarelto | $381 | $95,60963 claims |
| NovartisEntresto | $1,168 | $94,86775 claims |
| Boehringer IngelheimJardiance | $301 | $58,18853 claims |
| AstraZenecaFarxiga | $92 | $45,80539 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $78 | $26,22744 claims |
| Sanofi-aventis U.S. LLCMultaq | $340 | $11,57913 claims |
| Novo NordiskOzempic | $86 | $9,13911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in West Hills
- Farhad RafiiWest Hills$3.2M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.